Verrica Pharmaceuticals Inc. Increase (Decrease) in Accounts Payable
Verrica Pharmaceuticals Inc. (VRCA) reported Increase (Decrease) in Accounts Payable of -$469.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$590.00K, a 167.20% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $121.00K.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $487.00K, a 47.69% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$736.00K.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2025 was $176.00K.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2024 was -$568.00K, a 125.81% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2023 was $2.20M.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2022 was -$338.00K, a 168.01% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$590.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$469.00K 10-Q · filed 2026-08-06 | $18.00K derived: sum of 3 quarters · filed 2026-08-06 | -$718.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $121.00K 10-Q · filed 2026-05-12 | $608.00K derived: sum of 2 quarters · filed 2026-05-12 | -$128.00K derived: sum of 3 quarters · filed 2026-05-12 | $750.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $487.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$249.00K derived: sum of 2 quarters · filed 2026-03-11 | $629.00K derived: sum of 3 quarters · filed 2026-08-06 | $176.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | -$736.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $142.00K derived: sum of 2 quarters · filed 2026-08-06 | -$311.00K 10-Q · filed 2025-11-14 | $620.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $878.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $425.00K 10-Q · filed 2026-08-06 | $1.36M derived: sum of 3 quarters · filed 2026-08-06 | $1.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$453.00K 10-Q · filed 2026-05-12 | $478.00K derived: sum of 2 quarters · filed 2026-05-12 | $309.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.07M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $931.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $762.00K derived: sum of 2 quarters · filed 2026-03-11 | -$620.00K derived: sum of 3 quarters · filed 2026-03-11 | -$568.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | -$169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.55M derived: sum of 2 quarters · filed 2025-11-14 | -$1.50M 10-Q · filed 2025-11-14 | -$921.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.33M 10-Q · filed 2025-08-12 | -$752.00K derived: sum of 3 quarters · filed 2025-08-12 | -$631.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $52.00K 10-Q · filed 2025-05-13 | $630.00K derived: sum of 2 quarters · filed 2025-05-13 | $751.00K derived: sum of 3 quarters · filed 2025-05-13 | $2.24M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $578.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $699.00K derived: sum of 2 quarters · filed 2025-03-11 | $2.19M derived: sum of 3 quarters · filed 2025-03-11 | $2.20M 10-K · filed 2025-03-11 |
| 2023-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.61M derived: sum of 2 quarters · filed 2024-11-05 | $1.62M 10-Q · filed 2024-11-05 | $1.99M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.50M 10-Q · filed 2024-08-14 | $1.87M derived: sum of 3 quarters · filed 2024-08-14 | $1.29M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $14.00K 10-Q · filed 2024-05-13 | $384.00K derived: sum of 2 quarters · filed 2024-05-13 | -$193.00K derived: sum of 3 quarters · filed 2024-05-13 | -$10.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$207.00K derived: sum of 2 quarters · filed 2024-02-29 | -$24.00K derived: sum of 3 quarters · filed 2024-02-29 | -$338.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | -$577.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$394.00K derived: sum of 2 quarters · filed 2023-11-09 | -$708.00K 10-Q · filed 2023-11-09 | -$733.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$131.00K 10-Q · filed 2023-08-08 | -$156.00K derived: sum of 3 quarters · filed 2023-08-08 | -$69.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$314.00K 10-Q · filed 2023-05-09 | -$339.00K derived: sum of 2 quarters · filed 2023-05-09 | -$252.00K derived: sum of 3 quarters · filed 2023-05-09 | -$342.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $62.00K derived: sum of 2 quarters · filed 2023-03-06 | -$28.00K derived: sum of 3 quarters · filed 2023-03-06 | $497.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$3.00K derived: sum of 2 quarters · filed 2022-11-07 | $522.00K 10-Q · filed 2022-11-07 | $690.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $435.00K 10-Q · filed 2022-08-11 | $603.00K derived: sum of 3 quarters · filed 2022-08-11 | -$515.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $525.00K 10-Q · filed 2022-05-09 | $693.00K derived: sum of 2 quarters · filed 2022-05-09 | -$425.00K derived: sum of 3 quarters · filed 2022-05-09 | -$231.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$950.00K derived: sum of 2 quarters · filed 2022-03-02 | -$756.00K derived: sum of 3 quarters · filed 2022-03-02 | -$838.00K 10-K · filed 2022-03-02 |
| 2020-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$924.00K derived: sum of 2 quarters · filed 2021-11-12 | -$1.01M 10-Q · filed 2021-11-12 | -$832.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $194.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $112.00K 10-Q · filed 2021-08-10 | $286.00K derived: sum of 3 quarters · filed 2021-08-10 | $342.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$82.00K 10-Q · filed 2021-05-07 | $92.00K derived: sum of 2 quarters · filed 2021-05-07 | $148.00K derived: sum of 3 quarters · filed 2021-05-07 | -$34.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $230.00K derived: sum of 2 quarters · filed 2021-03-17 | $48.00K derived: sum of 3 quarters · filed 2021-03-17 | $263.00K 10-K · filed 2021-03-17 |
| 2019-09-30 | $56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$126.00K derived: sum of 2 quarters · filed 2020-11-09 | $89.00K 10-Q · filed 2020-11-09 | -$56.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$182.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $33.00K 10-Q · filed 2020-08-05 | -$112.00K derived: sum of 3 quarters · filed 2020-08-05 | $229.00K derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $215.00K 10-Q · filed 2020-05-07 | $70.00K derived: sum of 2 quarters · filed 2020-05-07 | $411.00K derived: sum of 3 quarters · filed 2020-05-07 | $527.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $196.00K derived: sum of 2 quarters · filed 2020-03-13 | $312.00K derived: sum of 3 quarters · filed 2020-03-13 | $769.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $457.00K derived: sum of 2 quarters · filed 2019-11-06 | $914.00K 10-Q · filed 2019-11-06 | $290.00K derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $573.00K 10-Q · filed 2019-08-07 | -$51.00K derived: sum of 3 quarters · filed 2019-08-07 | $356.00K derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $457.00K 10-Q · filed 2019-05-07 | -$167.00K derived: sum of 2 quarters · filed 2019-05-07 | $240.00K derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | -$624.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$217.00K derived: sum of 2 quarters · filed 2019-03-07 | $86.00K 10-K · filed 2019-03-07 | |
| 2017-09-30 | $407.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $710.00K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $303.00K 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |